Education
About Us
Working with TipRanks
Follow Us
ProMIS Neurosciences (PMN)
NASDAQ:PMN
PMN Stock Chart & Stats
$0.48
-$0.04(-3.74%)
At close: 4:00 PM EST
$0.48
-$0.04(-3.74%)
Day’s Range― - ―
52-Week Range$0.38 - $1.59
Previous CloseN/A
Volume32.49K
Average Volume (3M)2.53M
Market Cap
$25.39M
Enterprise Value$12.32M
Total Cash (Recent Filing)$4.54M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta0.73
Next Earnings
Nov 12, 2025EPS Estimate
-0.24Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.29
Shares Outstanding51,806,496
10 Day Avg. Volume1,174,948
30 Day Avg. Volume2,534,945
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap0.49
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-1.46
Forecast
1Y Price Target
$5.00Price Target Upside941.67% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
Bulls Say, Bears Say
Bulls Say
Clinical TrialsThe steady progress in the P1b study, combined with positive safety review, positions ProMIS to deliver interim data and final 12-month topline results, both significant events for PMN shares.
Financial StabilityProMIS further strengthened its balance sheet by raising $21.6M in gross proceeds through July 2025 financing activities and launching an ~$18M ATM offering, which combined should provide funding into 2026.
Regulatory ProgressThe FDA has granted Fast Track designation to PMN310, potentially accelerating its approval process for treating Alzheimer's disease.
Bears Say
Financial ConcernsPipeline seems interesting, but funding is an issue.
Market CompetitionPMN310 shows no binding to amyloid plaque, unlike rival antibodies, potentially reducing the risk of amyloid-related imaging abnormalities (ARIA).
ProMIS Neurosciences News
PMN FAQ
What was ProMIS Neurosciences’s price range in the past 12 months?
ProMIS Neurosciences lowest stock price was $0.38 and its highest was $1.59 in the past 12 months.
What is ProMIS Neurosciences’s market cap?
ProMIS Neurosciences’s market cap is $25.39M.
When is ProMIS Neurosciences’s upcoming earnings report date?
ProMIS Neurosciences’s upcoming earnings report date is Nov 12, 2025 which is in 28 days.
How were ProMIS Neurosciences’s earnings last quarter?
ProMIS Neurosciences released its earnings results on Aug 13, 2025. The company reported -$0.29 earnings per share for the quarter, missing the consensus estimate of -$0.174 by -$0.116.
Is ProMIS Neurosciences overvalued?
According to Wall Street analysts ProMIS Neurosciences’s price is currently Undervalued.
Does ProMIS Neurosciences pay dividends?
ProMIS Neurosciences does not currently pay dividends.
What is ProMIS Neurosciences’s EPS estimate?
ProMIS Neurosciences’s EPS estimate is -0.24.
How many shares outstanding does ProMIS Neurosciences have?
ProMIS Neurosciences has 51,806,496 shares outstanding.
What happened to ProMIS Neurosciences’s price movement after its last earnings report?
ProMIS Neurosciences reported an EPS of -$0.29 in its last earnings report, missing expectations of -$0.174. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of ProMIS Neurosciences?
Currently, no hedge funds are holding shares in PMN
ProMIS Neurosciences Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$5.00 (941.67% Upside)
$5.00 (941.67% Upside)
Insider Transactions
Bought Shares
Worth $14.9K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 6.8%
Last 30 Days ▲ 14.4%
Last 30 Days ▲ 14.4%
News Sentiment
Neutral
Bullish news 50%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-52.94%
12-Months-Change
Fundamentals
Return on Equity
-19.56%
Trailing 12-Months
Asset Growth
574.63%
Trailing 12-Months
Company Description
ProMIS Neurosciences
ProMIS Neurosciences, Inc. discovers and develops precision medicine solutions for the treatment of neurodegenerative diseases, primarily Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA) in Canada. The company's proprietary discovery platform comprises ProMIS and Collective Coordinates algorithms to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins. Its lead product candidates include PMN310, a monoclonal antibody (mAb) for toxic oligomers in AD; PMN267, a superoxide dismustase 1 and TAR-DNA binding protein 43 in ALS, as well as alpha synuclein in Parkinson's disease and Lewy body dementia; and PMN442, a mAb targeting toxic a-syn oligomers and seeding fibrils in MSA. The company was formerly known as Amorfix Life Sciences Ltd. and changed its name to ProMIS Neurosciences, Inc. in July 2015. ProMIS Neurosciences, Inc. was incorporated in 2004 and is headquartered in Toronto, Canada.
PMN Stock 12 Month Forecast
Average Price Target
$5.00
▲(941.67% Upside)
Technical Analysis
Minerva Neurosciences
―
Bolt Biotherapeutics
―
Cognition Therapeutics
―
Neurosense Therapeutics Ltd.
―
Jupiter Neurosciences, Inc.
―
Ownership Overview
40.79% Insiders
0.03% Mutual Funds
0.24% Other Institutional Investors
58.94% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---